Retrospective cohort study on the safety and efficacy of bevacizumab for metastatic colorectal cancer patients: The HGCSG0801study-Analysis of bevacizumab beyond progression (BBP).

被引：0
|
作者：
Fukushima, Hiraku
Yuki, Satoshi
Kobayashi, Yoshimitsu
Hatanaka, Kazuteru
Kusumi, Takaya
Hosokawa, Ayumu
Miyagishima, Takuto
Takeuchi, Satoshi
Kudo, Mineo
Komatsu, Yoshito
机构：
[1] Tomakomai City Hosp, Dept Gastroenterol, Tomakomai, Japan
[2] Hokkaido Univ, Sch Med, Dept Gastroenterol, Sapporo, Hokkaido, Japan
[3] Hakodate City Hosp, Dept Gastroenterol, Hakodate, Hokkaido, Japan
[4] Keiyukai Sapporo Hosp, Sapporo, Hokkaido, Japan
[5] Toyama Univ, Toyama, Japan
[6] Kushiro Rosai Hosp, Dept Internal Med, Kushiro, Japan
[7] Hokkaido Univ Hosp, Dept Med Oncol, Sapporo, Hokkaido, Japan
[8] Sapporo Hokuyu Hosp, Dept Gastroenterol, Sapporo, Hokkaido, Japan
[9] Hokkaido Univ Hosp, Dept Canc Ctr, Sapporo, Hokkaido, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 04期
关键词：
D O I：
10.1200/jco.2012.30.4_suppl.684
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
684
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Phase II study to evaluate efficacy and safety of irinotecan, capecitabine, and bevacizumab in patients with metastatic colorectal cancer (mCRC)
    Garcia Alfonso, P.
    Chaves, M.
    Munoz Martin, A.
    Salud Salvia, A.
    Vilchez, R.
    Yuste, A.
    Gravalos Castro, C.
    Queralt Merino, B.
    Gonzalez Flores, E.
    Lopez Ladron, A.
    Losa, F.
    Oltra Ferrando, A.
    Gomez Reina, M. J.
    Campos, J. M.
    Aranda, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [42] PHASE II STUDY TO EVALUATE EFFICACY AND SAFETY OF IRINOTECAN, CAPECITABINE AND BEVACIZUMAB IN METASTATIC COLORECTAL CANCER (MCRC) PATIENTS
    Garcia Alfonso, Pilar
    Chaves, Manuel
    Munoz, Andres
    Salud, Antonieta
    Garcia-Giron, Carlos
    Gravalos, Cristina
    Massuti, Bartomeu
    Gonzalez-Flores, Encarnacion
    Queralt, Bernardo
    Lopez-Ladron, Amelia
    Losa, Ferran
    Oltra, Amparo
    Jose Gomez, Ma
    Manuel Campos, J.
    Aranda, Enrique
    ANNALS OF ONCOLOGY, 2012, 23 : 103 - 104
  • [43] Phase II study to evaluate efficacy and safety of irinotecan, capecitabine, and bevacizumab in metastatic colorectal cancer (mCRC) patients
    Garcia Alfonso, Pilar
    Chaves-Conde, Manuel
    Munoz, Andres
    Salud, Antonia
    Garcia-Giron, Carlos
    Gravalos Castro, Cristina
    Massuti, Bartomeu
    Gonzalez Flores, Encarnacion
    Queralt, Bernardo
    Lopez Ladron, Amelia
    Losa, Ferran
    Oltra Ferrando, Amparo
    Gomez Reina, Maria Jose
    Garcia-Carbonero, Rocio
    Garcia-Escobar, Ignacio
    Aranda, Enrique
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [44] OBSERVATIONAL COHORT STUDY OF 1ST LINE BEVACIZUMAB COMBINED WITH CHEMOTHERAPY IN METASTATIC COLORECTAL CANCER: HGCSG0802
    Nakamura, Michio
    Yuki, Satoshi
    Harada, Kazuaki
    Kobayashi, Yoshimitsu
    Kato, Takashi
    Uebayashi, Minoru
    Sonoda, Norikazu
    Eto, Kazunori
    Takahata, Takenori
    Komatsu, Yoshito
    ANNALS OF ONCOLOGY, 2014, 25
  • [45] Clinical outcomes in bevacizumab (BV)-treated patients (pts) with metastatic colorectal cancer (mCRC): Results from ARIES observational cohort study (OCS) and confirmation of BRITE data on BV beyond progression (BBP)
    Cohn, A. L.
    Bekaii-Saab, T.
    Bendell, J. C.
    Hurwitz, H.
    Kozloff, M.
    Roach, N.
    Tezcan, H.
    Feng, S.
    Sing, A.
    Grothey, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [46] Modified FOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab beyond first progression in advanced colorectal cancer: CCOG-0801 study.
    Ishigure, Kiyoshi
    Nakayama, Goro
    Uehara, Keisuke
    Yokoyama, Hiroyuki
    Ishiyama, Akiharu
    Eguchi, Takehiko
    Tsuboi, Kenji
    Ando, Yuichi
    Kodera, Yasuhiro
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [47] A retrospective cohort study evaluating the safety and efficacy of TAS-102 in patients with metastatic colorectal cancer (HGCSG1503): Analysis of cases of prior regorafenib.
    Ishiguro, Atsushi
    Yuki, Satoshi
    Nakatsumi, Hiroshi
    Saiki, Takuro
    Tsuji, Yasushi
    Hatanaka, Kazuteru
    Yoshita, Hiroki
    Minami, Shinya
    Ohta, Tomoyuki
    Eto, Kazunori
    Nakajima, Junta
    Nakamura, Michio
    Suzuki, Kazuhiro
    Koike, Masahiko
    Kato, Kanji
    Tateyama, Miki
    Asada, Chiaki
    Sekiguchi, Mari
    Sakata, Yuh
    Komatsu, Yoshito
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [48] BEVACIZUMAB plus CHEMOTHERAPY BEYOND FIRST PROGRESSION IN METASTATIC COLORECTAL CANCER PATIENTS PREVIOUSLY TREATED WITH BEVACIZUMAB-BASED THERAPY: TML STUDY SUBGROUP FINDINGS
    Andre, Thierry
    Jose Maria, Vieitez
    Bouche, Olivier
    Bennouna, Jaafar
    Sastre, Javier
    Alonso-Orduna, Vicente
    Arnold, Dirk
    Osterlund, Pia
    Greil, Richard
    Van Cutsem, Eric
    von Moos, Roger
    Reyes-Rivera, Irmarie
    Makrutzki, Martina
    Kubicka, Stefan
    ANNALS OF ONCOLOGY, 2012, 23 : 14 - 14
  • [49] Efficacy and safety of regorafenib in the treatment of metastatic colorectal cancer: a retrospective cohort study
    Yan, Hao
    Liu, Jindong
    Zhang, Yifan
    Chen, Shuo
    Xu, Jing
    Gao, Dandan
    Li, Haipeng
    Fang, Xinyue
    Wang, Yu
    Wang, Huaqing
    Wang, Hui
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2024, 15 (03) : 987 - 1001
  • [50] A retrospective analysis of periodontitis during bevacizumab treatment in metastatic colorectal cancer patients
    Ogawa, Kohei
    Ueno, Takao
    Kato, Ken
    Nishitani, Hitoshi
    Akiyoshi, Kohei
    Iwasa, Satoru
    Nakajima, Takako Eguchi
    Hamaguchi, Tetsuya
    Yamada, Yasuhide
    Hosokawa, Ayumu
    Sugiyama, Toshiro
    Shimada, Yasuhiro
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2013, 18 (06) : 1020 - 1024
12345